Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
161-180 of 998 trials

Mucopolysaccharidosis Type II: DNL310 Treatment Study

We are investigating the long-term safety and effects of DNL310 in patients with MPS II. This study looks at how well the treatment works for cognitive and physical development.

Hunter's Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyNeurology

Mild Male Factor Infertility: PKB171 Gel Study

We are testing a new intravaginal gel to see if it helps couples with mild male factor infertility achieve pregnancy. The study compares the gel's effects to a placebo over three treatment cycles.

Male Infertility6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteGynecology and ObstetricsUrology

Endometrial Cancer: Olaparib Maintenance Therapy

We are studying whether olaparib can help prevent cancer recurrence in patients with p53abn endometrial cancer after they receive chemoradiation. This trial compares olaparib treatment to observation alone.

p53abn HREC Patients Post-Surgery>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteGynecology and ObstetricsOncology

Locally Advanced NSCLC: Alectinib vs. Durvalumab

We are studying whether alectinib or entrectinib is more effective than durvalumab for patients with advanced non-small cell lung cancer who have not progressed after initial treatment. The trial also looks at quality of life and safety for participants.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Progressive Glioblastoma: Perampanel Treatment Study

We are studying whether the medication Perampanel can help reduce tumor growth in patients with progressive glioblastoma before surgery. This trial also looks at quality of life and cognitive function to see how the treatment affects patients.

Progressive Glioblastoma>2 yearsEfficacy phase (II)Standard MedicinesPartially RemoteNeurologyOncology

Pneumonia: TAD® Treatment Study

We are testing whether TAD®, an intravenous treatment, can help prevent heart injury in hospitalized patients with pneumonia. This study aims to evaluate its safety and effectiveness as an additional therapy.

Heart Injury from Pneumonia1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal MedicinePulmonology

Anifrolumab for Polymyositis and Dermatomyositis

We are studying whether Anifrolumab can improve muscle strength and reduce corticosteroid use in adults with polymyositis and dermatomyositis compared to a placebo.

Polymyositis and Dermatomyositis>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesRheumatology

Guselkumab for Crohn's Disease Healing

We are studying whether guselkumab can help heal the intestinal wall in patients with Crohn's disease. This research aims to find out how effective it is over 48 weeks.

Crohn's Disease>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Alectinib for Pediatric ALK Fusion-Positive Tumors

We are studying the safety and effectiveness of alectinib in children with solid or CNS tumors that have not responded to other treatments. This trial aims to find the best dose and understand how the drug works in young patients.

Malignant Mast Cell TumorsALK Fusion-Positive Tumors>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPediatrics

Fibrodysplasia Ossificans Progressiva: INCB000928 Study

We are testing a new medication, INCB000928, to see if it can prevent new bone growth in people with Fibrodysplasia Ossificans Progressiva. The study will also evaluate the safety and tolerability of this treatment.

Fibrodysplasia Ossificans Progressiva>2 yearsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineOrthopedics and Traumatology

Breast Cancer: Stopping CDK4/6 Inhibitors

We are studying whether stopping CDK4/6 inhibitors helps maintain disease stability in patients with metastatic HR positive, HER2 negative breast cancer. This trial involves patients who have had stable disease after long-term treatment.

Metastatic HR Positive, HER2 Negative Breast Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Alpelisib for Lymphatic Malformations with PIK3CA Mutation

We are studying whether alpelisib can improve symptoms and imaging results in adults and children with lymphatic malformations caused by a PIK3CA mutation. Participants will be compared to those receiving a placebo to assess the treatment's effectiveness.

Lymphangioma>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Nipocalimab for Generalized Myasthenia Gravis

We are studying whether nipocalimab IV infusions can help adults with generalized myasthenia gravis perform daily activities better than a placebo. This research aims to assess its effectiveness and safety.

Myasthenia Gravis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Atopic Eczema: Dupilumab Dosing Study

We are studying how different dosing schedules of dupilumab affect people with controlled atopic eczema. The goal is to see which schedule works best for managing symptoms and improving quality of life.

Atopic Eczema3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteAllergologyDermatology

Advanced Breast Cancer: Saruparib and Camizestrant Study

We are studying a new combination treatment for adults with advanced hormone receptor-positive, HER2-negative breast cancer. The goal is to see if it helps patients live longer without disease progression compared to standard therapies.

Advanced Breast CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOncology

Long-Term Follow-Up for Gene-Modified T Cell Treatment

We are monitoring patients treated with gene-modified T cells to assess any delayed side effects and the long-term effectiveness of the treatment. This study also looks at the health of younger patients who received this therapy.

Malignant Lymphoid Neoplasm>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineOncology

Community-Acquired Pneumonia: Customized Antibiotic Duration Study

We are investigating whether a new strategy for shortening antibiotic treatment is as effective as standard care for hospitalized patients with pneumonia. This study aims to improve patient outcomes while reducing unnecessary antibiotic use.

Community-acquired Pneumonia>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal MedicinePulmonology

Prostate Cancer: AZD5305 Treatment Study

We are studying whether AZD5305, combined with standard hormonal treatments, can improve outcomes for men with metastatic castration-sensitive prostate cancer. This trial compares the new treatment to a placebo to assess its effectiveness.

Metastatic Castration-Sensitive Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Autoimmune Encephalitis: Satralizumab Study

We are testing the effectiveness and safety of satralizumab in patients with NMDAR or LGI1 mediated autoimmune encephalitis. The study aims to see if it improves disability and reduces symptoms compared to a placebo.

Autoimmune Encephalitis>2 yearsConfirmation phase (III)Post-Trial Drug AccessPartially RemoteNeurologyRheumatology

Eosinophilic Granulomatosis With Polyangiitis: NS-229 Study

We are testing a new treatment, NS-229, to see if it helps patients with Eosinophilic Granulomatosis With Polyangiitis achieve remission better than a placebo. The study will also look at any side effects and the time until symptoms worsen.

Eosinophilic Granulomatosis with Polyangiitis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesRheumatology